Power3, Methodist Hospital, GE Healthcare, Merrill Lynch, Waters, Broad Institute, Max Planck, Rosetta Biosoftware, GeneGo, University of Aberystwyth, Caliper | GenomeWeb

Power3, Methodist Hospital Partner on Biomarker-Based Blood Tests for Neurodegenerative Disease

Power3 Medical Products and the Methodist Hospital Research Institute have partnered to search for protein biomarkers and develop a suite of tests for the diagnosis of neurodegenerative disease, Power3 said this week.

In collaboration with Stan Appel, chair of neurology at Methodist Neurological Institute, Power3 has completed clinical validation by testing serum proteins from more than 600 patients with Lou Gehrig's, Alzheimer's, and Parkinson's disease.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.